REPLIMUNE GROUP INC. - COMMON STOCK

Replimune Announces Proposed Public Offering

25 Nov 2024 07:09:26 By Nasdaq GlobeNewswire

Replimune Receives Breakthrough Therapy Designation for RP1 and Submits RP1 Biologics License Application to the FDA under the Accelerated Approval Pathway

21 Nov 2024 16:05:00 By Nasdaq GlobeNewswire

Replimune Reports Fiscal Second Quarter 2025 Financial Results and Provides Corporate Update

12 Nov 2024 08:00:02 By Nasdaq GlobeNewswire

Replimune Presents Late-Breaking Abstract Featuring Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024)

09 Nov 2024 13:00:00 By Nasdaq GlobeNewswire

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

08 Nov 2024 16:01:00 By Nasdaq GlobeNewswire

Replimune to Present at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

30 Oct 2024 09:15:09 By Nasdaq GlobeNewswire

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

09 Oct 2024 16:01:00 By Nasdaq GlobeNewswire

Replimune to Present at Two Upcoming Investor Conferences

01 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024

15 Sep 2024 09:45:00 By Nasdaq GlobeNewswire

Replimune Announces Positive Pre-BLA Meeting with FDA and Confirms BLA Submission On Track for 2H 2024

09 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Stockholders Vote to Elect Madhavan Balachandran to Board of Directors

05 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Replimune Announces Late-Breaking Abstract of IGNYTE Clinical Trial Primary Analysis Selected for Oral Presentation at the European Society for Medical Oncology (ESMO) Congress 2024

22 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma

13 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Replimune Reports Fiscal First Quarter 2025 Financial Results and Provides Corporate Update

08 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Replimune to Present at Two Upcoming Investor Conferences

30 Jul 2024 16:01:00 By Nasdaq GlobeNewswire

Replimune Announces $100 Million Private Placement Financing

13 Jun 2024 08:30:00 By Nasdaq GlobeNewswire

Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

07 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

Replimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma

06 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Replimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

03 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

Replimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

23 May 2024 17:00:00 By Nasdaq GlobeNewswire